文献速递淋巴瘤

40例原发系统型间变性大细胞淋巴瘤的临床特征及预后因素分析

[Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

回顾性分析浙江大学医学院附属第一医院2013年1月至2018年12月收治的40例原发系统型间变性大细胞淋巴瘤(ALCL)患者临床资料,总结临床特征及预后因素。结果显示患者以男性为主,多数为Ann Arbor分期Ⅲ~Ⅳ期伴结外侵犯;ALK阴性(P=0.029,OR=13.458)和Ki-67≥80%(P=0.04,OR=14.453)是完全缓解(CR)的独立影响因素,ECHOP方案CR率高于CHOP方案。

要点

  • 40例中位年龄41(14~67)岁,男29例、女11例,Ⅲ~Ⅳ期36例(90.0%),结外侵犯38例(95.0%)。
  • ALK阳性22例(55.0%)中位年龄29(14~67)岁,ALK阴性18例(45.0%)中位年龄51.5(19~67)岁,P=0.003。
  • ALK阴性(P=0.029,OR=13.458)和Ki-67≥80%(P=0.04,OR=14.453)是CR的独立影响因素。

核心结论

  • 原发系统型ALCL男性居多,ALK阳性患者中位年龄29(14~67)岁低于ALK阴性患者51.5(19~67)岁,P=0.003。
  • 诊断时多为Ⅲ~Ⅳ期伴结外侵犯,半数以上有B症状、LDH升高、Ki-67高表达。
  • Ki-67表达水平、ALK表达及化疗方案对CR率有预后价值,LDH水平、IPI评分、ALK表达及化疗方案对PFS和OS有预后价值。
  • 作者认为ECHOP是较优的化疗方案,可改善预后。

研究设计与样本

  • 回顾性分析2013年1月至2018年12月浙江大学医学院附属第一医院住院治疗的40例原发系统型ALCL患者临床资料。

主要发现

  • 中位年龄41(14~67)岁,男29例、女11例,Ann Arbor分期Ⅲ~Ⅳ期36例(90.0%),IPI中高危、高危23例(57.5%)。
  • B症状25例(62.5%),结外侵犯38例(95.0%),LDH升高25例(62.5%),Ki-67≥80% 25例(62.5%)。
  • ALK阳性22例(55.0%),ALK阴性18例(45.0%),两组中位年龄29(14~67)岁 vs 51.5(19~67)岁,P=0.003。
  • 全部40例接受化疗,CHOP方案18例、ECHOP方案12例、其他方案10例,26例(65.0%)获得CR。
  • ECHOP方案CR率83.3%(10/12)高于CHOP方案38.9%(7/18),P=0.026。

关键数值与推荐

  • ALK阴性(P=0.029,OR=13.458)和Ki-67≥80%(P=0.04,OR=14.453)是CR的独立影响因素。
  • ECHOP方案CR率83.3%(10/12)高于CHOP方案38.9%(7/18),P=0.026。
  • LDH水平、IPI评分、ALK表达及化疗方案对PFS和OS影响有统计学意义(P<0.05)。

临床怎么用

  • 作者认为ECHOP是较优的化疗方案,可改善预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the clinical features and prognostic factors of primary systemic anaplastic large cell lymphoma (ALCL) . Methods: 40 ALCL cases treated in the First Affiliated Hospital of Zhejiang University from January 2013 to December 2018 were retrospectively analyzed. Results: ① With a median age of 41 (14-67) years, there were 29 males and 11 females, 36 patients (90.0%) had Ann Arbor stage Ⅲ-Ⅳ tumors, 23 patients (57.5%) were in high-intermediate or high international prognostic index (IPI) risk group. 25 patients (62.5%) had B symptoms, such as fever, emaciation and night sweat.38 patients (95.0%) had extranodal invasion, 25 patients (62.5%) had higher LDH level, and 25 patients (62.5%) had high expression of Ki-67 (80% or more) . With 22 ALK(+) patients (55.0%) and 18 ALK(-) patients (45.0%) , there was a significantly difference in the median age of the two groups [29 (14-67) years old vs 51.5 (19-67) years old, P=0.003]. ② All patients received chemotherapy, 18 cases were treated with CHOP (cyclophosphamide, doxorubicin, vindesine, prednisone) , 12 cases with ECHOP (cyclophosphamide, doxorubicin, vindesine, prednisone, etoposide) , 10 cases with other treatments and 26 patients (65.0%) obtained complete remission (CR) . ALK(-) (P=0.029, OR=13.458) and Ki-67 expression of 80% or more (P=0.04, OR=14.453) were independent factors of CR rate, the CR rate of ECHOP chemotherapy was higher than CHOP chemotherapy (P=0.026) . ③ LDH level, IPI score, ALK expression and chemotherapy regimen had significantly effect on progression free survival (PFS) and overall survival (OS) (P<0.05) . Conclusion: The study shows that primary systemic ALCL usually occurs in males, the average age of ALK(+) patients were younger than ALK(-) patients. Most patients are in stage Ⅲ-Ⅳ with extranodal invasion, more than half of the patients have B symptoms, elevated LDH, and high expression of Ki-67. The expression level of Ki-67, ALK expression, and chemotherapy regimen have prognostic value for CR rate, the LDH level, IPI score, ALK expression and chemotherapy regimen for PFS and OS. ECHOP is a better choice with improved prognosis. 目的: 分析原发系统型间变性大细胞淋巴瘤(ALCL)的临床特征及预后因素。 方法: 回顾性分析2013年1月至2018年12月期间在浙江大学医学院附属第一医院住院治疗的40例ALCL患者的临床资料,总结其临床特征并分析其预后相关因素。 结果: ①40例患者中男29例,女11例,中位年龄41(14~67)岁,Ann Arbor分期Ⅲ~Ⅳ期36例(90.0%),IPI评分中高危、高危23例(57.5%);25例(62.5%)有B症状,发热最为常见,其次为消瘦、盗汗;38例(95.0%)有结外侵犯;25例(62.5%)LDH升高;25例(62.5%)Ki-67≥80%;ALK阳性22例(55.0%),中位年龄29(14~67)岁,ALK阴性18例(45.0%),中位年龄51.5(19~67)岁,年龄差异有统计学意义(P=0.003)。②40例患者均接受化疗,采用CHOP(环磷酰胺+多柔比星+长春地辛+泼尼松)方案18例,ECHOP(依托泊苷+CHOP)方案12例,其他方案10例;26例(65.0%)获得完全缓解(CR),ALK阴性(P=0.029,OR=13.458)和Ki-67≥80%(P=0.04,OR=14.453)是CR的独立影响因素,ECHOP方案的CR率高于CHOP方案[83.3%(10/12)对38.9%(7/18),P=0.026]。③LDH水平、IPI评分、ALK表达情况以及化疗方案的选择对无进展生存(PFS)和总生存(OS)影响有统计学意义(P<0.05)。 结论: ALCL发病男性居多,青少年至中老年均有发病,ALK阳性中年轻患者居多,诊断时临床分期晚,多数患者有结外侵犯,半数以上患者有B症状、LDH升高、Ki-67高表达;ALK表达与否、Ki-67表达水平以及化疗方案的选择可影响疗效,LDH水平、IPI评分、ALK表达与否以及化疗方案的选择可影响PFS和OS;ECHOP是较优的化疗方案,可改善预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen YK, Yu WJ, Liu H, et al. [Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32311892. doi:10.3760/cma.j.issn.0253-2727.2020.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。